In these preclinical models of human colorectal cancer, the combination of an anti-HER2 antibody (pertuzumab or trastuzumab) and an HER2 tyrosine kinase inhibitor (TKI) (lapatinib) induced pronounced tumor shrinkage [17]. This evidence concerns the gene ERBB2 and neoplasm.